Status:
COMPLETED
Japanese Dose-Response Study of Rimonabant in Obese Patients
Lead Sponsor:
Sanofi
Conditions:
Obesity
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
Brief Summary
The primary objective is to verify the dose-response relationship of rimonabant on body weight change. The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body we...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Body Mass Index ≥25 kg/m²
- Viceral Fat Area ≥ 100 cm²
- Diet therapy for more than 8 weeks before start of the placebo observation period
- Stable weight (variation \< ±3kg within 8 weeks before start of observation period)
- At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDL-choresterol), Hypertension
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
527 Patients enrolled
Trial Details
Trial ID
NCT00459004
Start Date
October 1 2004
End Date
April 1 2006
Last Update
April 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Tokyo, Japan